Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Biktarvy has a lower rate of adverse health events, according to 96-week data.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.
Full 48-week results comparing Tivicay plus Epivir with Tivicay plus Truvada were presented at the International AIDS Conference.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.
The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.
Published results have updated preliminary findings presented at a previous conference.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
HIV researcher David Alain Wohl, MD, urges AIDS activists to be a vanguard against indifference, overreach and shortsightedness.
Writer Anna Forbes responds to an open letter by HIV researcher David Alain Wohl, MD, that urges AIDS activists to do more.
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS.
HIV scientists and advocates are waging a powerful war against the global epidemic.
The social media buzz on the annual HIV science conference.
Truvada metabolizes differently in the vagina than in the rectum, leaving less room for error in protecting vaginal tissues from HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.